Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (112)

IV-001Gianluca Selvaggio

Physiologically based pharmacokinetic modelling to support design of microarray patches delivering antiretroviral drugs to HIV positive children

Thursday 15:00-16:30

IV-002Carlos Serra Traynor

DeepCIM: Prediction of myelosuppressive anti-cancer molecules using drug-target interaction datasets

Thursday 15:00-16:30

IV-003Alejandro Serrano Alcaide

Relationship between tumor growth and Treg activation status to optimize a previously published Immune oncology framework

Thursday 15:00-16:30

IV-004Jérémy Seurat

Macrophage-induced reduction of bacteriophage density limits the efficacy of pulmonary phage therapy

Thursday 15:00-16:30

IV-005Chaozhuang Shen

A Physiologically-Based Quantitative Systems Pharmacology (PB-QSP) Model for Individualized Prediction of Treatment Outcomes with Alogliptin in the Renal Impairment Population

Thursday 15:00-16:30

IV-006Valerie Sia

Thursday 15:00-16:30

IV-007Anastasios Siokis

In-silico clinical trials in virtual asthma patients powered by QSP accelerated the development of lunsekimig

Thursday 15:00-16:30

IV-008Lucia Siovitz

Characterizing the Longitudinal Exposure-Response Relationship of Upadacitinib Efficacy in Vitiligo: Insights from Analysis of Phase 2 Clinical Data

Thursday 15:00-16:30

IV-010Erik Sjögren

Absorption, Bioavailability, and Immunogenicity after Subcutaneous Administration: Evaluation of a Subcutaneous Platform within the Open Systems Pharmacology framework

Thursday 15:00-16:30

IV-011Victor Sokolov

Quantitative Systems Pharmacology Model of Type 1 IFN-mediated Inflammation in Systemic Lupus Erythematosus

Thursday 15:00-16:30

IV-012Pooneh Soltantabar

Elranatamab Exposure-Safety Analysis in Patients with Relapse or Refractory Multiple Myeloma: Insights from MagnetisMM Studies

Thursday 15:00-16:30

IV-013Meemansa Sood

Lutathera dose determination and justification in adolescents via population PK and dosimetry modeling and simulation

Thursday 15:00-16:30

IV-014Tomas Sou

Population PK/PD modelling to evaluate the effect of siremadlin and disease progression on platelet dynamics in haematological malignancies

Thursday 15:00-16:30

IV-015Angelica Squarzoni

Pharmacodynamic Drug-Drug Interaction Between Oxaliplatin and HDAC Inhibitors in Colorectal Cancer Cell Lines

Thursday 15:00-16:30

IV-016Felix Stader

Physiologically based pharmacokinetic modelling to predict the concentration-time profile of an antibody-drug conjugate and hepatic and renal impairment.

Thursday 15:00-16:30

IV-017Britta Steffens

Pharmacometric analysis to explore moxidectin treatment with and without albendazole in Trichuris trichiura-infected adolescents

Thursday 15:00-16:30

IV-019Marie Steinacker

Combining biological knowledge and machine learning for predicting dynamics of haematotoxcity after chemotherapy: a comparative analysis

Thursday 15:00-16:30

IV-020Oleg Stepanov

Utilizing the AZD7442 Model for Accelerated New Drug Development: Pharmacokinetic Insights Across Infectious Disease Prevention and Passive Immunization

Thursday 15:00-16:30

IV-021Ida Storgaard

Population pharmacokinetic-pharmacodynamic model of subcutaneous bupivacaine in a novel extended-release microparticle formulation

Thursday 15:00-16:30

IV-022Hong Su

How should target-mediated drug disposition model be used for predicting receptor occupancy?

Thursday 15:00-16:30

IV-023ming sun

Bayesian PBPK modeling for acyclovir dose optimization for treating viral encephalitis

Thursday 15:00-16:30

IV-024Bae Sungyeun

Population pharmacokinetics of intravenous MIT-001 in healthy subjects and patients

Thursday 15:00-16:30

IV-025Mikael Sunnåker

A Generative Pre-trained Transformer for Time-Course and Dose-Response Predictions

Thursday 15:00-16:30

IV-026Budi Octasari Susanto

An integrative translational framework for in vitro modelling for macozinone to support prediction of early human anti-tubercular efficacy

Thursday 15:00-16:30

IV-027Jérémie Tachet

Population pharmacokinetic modelling of oral ruxolitinib: a real-world prospective observational study

Thursday 15:00-16:30

IV-028Sung Taewook

Optimizing IMC-001 Dosage Regimens Using Target Mediated Drug Disposition Model: Enhancing Therapeutic Efficacy and Safety in Cancer Treatment

Thursday 15:00-16:30

IV-029Zhiyuan Tan

Model-informed pazopanib dose optimization in real-world cancer patients

Thursday 15:00-16:30

IV-030Sebastian Tandar

Population-level treatment optimization using a multi-objective optimization strategy

Thursday 15:00-16:30

IV-031Olga Teplytska

Machine Learning algorithms for concentration prediction in anticancer drug therapy: Towards a method for individual dose adjustment

Thursday 15:00-16:30

IV-032David Ternant

Unveiling a “predator/prey” interplay of anti-CD19 CAR T-Cells and their targets in Relapsed/refractory DLBCL patients

Thursday 15:00-16:30

IV-033Adrien Tessier

Joint Modeling Of Longitudinal Circulating Tumor DNA And Survival In Metastatic Colorectal Cancer: A Promise Of Early Prediction Of Response In Oncology?

Thursday 15:00-16:30

IV-034Florencia Tettamanti

Predicting Progression Free Survival from Measurable Residual Disease (MRD) in Chronic Lymphocytic Leukemia (CLL)

Thursday 15:00-16:30

IV-035Donato Teutonico

Estimation of population parameter values and variability coupling non-linear mixed-effects modeling (based on SAEM algorithm) with a whole-body PBPK model

Thursday 15:00-16:30

IV-036Hoai-Thu Thai

A joint modeling approach leveraging intravenous data to support dose selection of subcutaneous isatuximab in combination with pomalidomide-dexamethasone in relapsed/refractory multiple myeloma

Thursday 15:00-16:30

IV-037Veena Thomas

Utility of Physiologically-based Pharmacokinetic Model to Predict Inter-Antibody Variability in Monoclonal Antibody Pharmacokinetics

Thursday 15:00-16:30

IV-038Charlotte M Thomas

Pharmacokinetic-Pharmacodynamic Modelling of Risankizumab in Plaque Psoriasis Real World Data

Thursday 15:00-16:30

IV-039Anders Thorsted

Item response theory-enabled translation between DAS28 and ACR – Key clinical endpoints within rheumatoid arthritis drug development

Thursday 15:00-16:30

IV-040Paul Thoueille

Pharmacometrics-based analysis of salmeterol and its metabolite α-hydroxysalmeterol in plasma and urine: practical implications for doping control

Thursday 15:00-16:30

IV-041Johannes Tillil

Automated QSP model order reduction combining multiple state-level reduction approaches

Thursday 15:00-16:30

IV-042Elena Tosca

Dealing with stochasticity in precision dosing decision-making processes by fully exploiting PK-PD modelling in Reinforcement Learning algorithms. A practical case-study on Vancomycin continuous infusion in ICU patients

Thursday 15:00-16:30

IV-043Mirjam Trame

FOCE generalized log-likelihood using nlmixr2

Thursday 15:00-16:30

IV-044Van Thuy Truong

Stochastic pharmacodynamics: Drug effects on the time to extinction of a heterogeneous tumour cell population

Thursday 15:00-16:30

IV-045Quan Truong

Underdosing imipenem in patients with renal insufficiency: global clinical data-driven pharmacokinetic/pharmacodynamic study

Thursday 15:00-16:30

IV-046Lufina Tsirizani

Population pharmacokinetics of ritonavir administered to boost lopinavir, atazanavir, or darunavir in children with HIV in Africa.

Thursday 15:00-16:30

IV-047Anastasia Tsyplakova

Population Pharmacokinetics of Valproic Acid, Lamotrigine, and Levetiracetam in the Pediatric Population

Thursday 15:00-16:30

IV-048Diego Valderrama

Integrating Random Effects in Scientific Machine Learning Models for Pharmacokinetic Modeling

Thursday 15:00-16:30

IV-049Debra van Asten

Population pharmacokinetics of ticagrelor and its active metabolite in a real-life hospitalized population

Thursday 15:00-16:30

IV-050Stijn van Beek

Population pharmacokinetic analysis of elafibranor and metabolite GFT1007 to support exposure-response characterization and dose selection in patients with primary biliary cholangitis

Thursday 15:00-16:30

IV-051Marinda van de Kreeke

Quantifying the sensitivity and specificity of CYP450 probe drugs in predicting in vivo enzyme activity under (patho)physiological conditions

Thursday 15:00-16:30

IV-052Stefan van den Berg

Pharmacokinetic model-informed precision dosing of natalizumab in Multiple Sclerosis

Thursday 15:00-16:30

IV-053Tamara van Donge

Middle-out physiologically-based pharmacokinetic modeling to support pediatric dosing recommendation for alectinib, an ALK tyrosine kinase receptor inhibitor

Thursday 15:00-16:30

IV-054Tamara van Donge

Population PK modeling of Vamikibart in aqueous humor, an anti-IL-6 monoclonal antibody, in patients with diabetic and uveitic macular edema

Thursday 15:00-16:30

IV-055Jennie van Dyk

Oral amoxicillin/clavulanate in paediatric patients with severe community acquired pneumonia: a popPK analysis from the PediCAP trial

Thursday 15:00-16:30

IV-056Marloes van Leuken

A population pharmacokinetic model of N,N-dimethyltryptamine administered through continuous intravenous infusion in healthy smokers and non-smokers

Thursday 15:00-16:30

IV-057Martje Van Neste

A semi-systematic review on the maturational physiology in exclusively breastfed infants: Growth – A contribution from the ConcePTION project

Thursday 15:00-16:30

IV-058Martijn van Noort

User-friendly parameter identifiability methods with a workflow to guide model development, using categorical and continuous scales

Thursday 15:00-16:30

IV-059Anne van Rongen

The impact of being born Small for Gestational Age (SGA) on the clearance of vancomycin versus morphine and midazolam

Thursday 15:00-16:30

IV-060Erno van Schaick

Population Pharmacokinetic Modeling of Leriglitazone in Healthy Volunteers and Patients with Neuro-degenerative Disorders – Exploring dosing schedules in children with adrenoleukodystrophy via simulations

Thursday 15:00-16:30

IV-061Daan van Valkengoed

Reliability of in vitro data for the mechanistic prediction of brain extracellular fluid pharmacokinetics of P-glycoprotein substrates in vivo; are we scaling correctly?

Thursday 15:00-16:30

IV-062Scott Van Wart

Population Pharmacokinetic (PK) and Pharmacokinetic-Pharmacodynamic (PK-PD) Modeling of Serum M-Protein in an Ongoing Phase 1/2 Study of Modakafusp Alfa in Patients with Relapsed/Refractory Multiple Myeloma

Thursday 15:00-16:30

IV-063Alberto Vegas

Modelling & simulation of biomarkers during anti-HIV monotherapy treatment

Thursday 15:00-16:30

IV-064Nieves Velez de Mendizabal

A circular PK/PD/PK model explains the exposure of bulevirtide and bile salts in adult patients with chronic hepatitis D

Thursday 15:00-16:30

IV-065Peter Velickovic

Translational pharmacology and dose rationale for imatinib and doramapimod as a host-directed therapy for the treatment of pulmonary tuberculosis

Thursday 15:00-16:30

IV-066Bharadwaj Vemparala

Modeling the influence of antiretroviral treatment initiation time on post-treatment control of HIV infection

Thursday 15:00-16:30

IV-067Esmée Vendel

Belimumab Pharmacokinetic Simulations to Select an Appropriate Subcutaneous Dosing Regimen to Treat Paediatric Patients with Active Lupus Nephritis

Thursday 15:00-16:30

IV-068Diego Vera-Yunca

Assessing clinical outcomes of nosocomial pneumonia patients with a pharmacometric multistate model

Thursday 15:00-16:30

IV-069Laura Villain

Considerations for the application of PBPK to optimize drug therapies in special populations: The Open Systems Pharmacology solutions

Thursday 15:00-16:30

IV-070Umberto Villani

Model-based characterisation of host-directed therapeutics against M. tuberculosis in an in vitro experimental model

Thursday 15:00-16:30

IV-071Roberto Visintainer

stormTB: SimulaTOR of a murine Minimal-pbpk model for anti-TB drugs

Thursday 15:00-16:30

IV-072Alina Volkova

Mathematical modeling of autoimmune diseases: a systematic review and analysis for advancing therapeutic development

Thursday 15:00-16:30

IV-073Jannik Vollmer

Combined population PK modelling of cefepime and enmetazobactam to characterize their individual and combined PK from the phase 1 to 3 studies

Thursday 15:00-16:30

IV-074Camille Vong

Multi-Endpoint Item-Response Modelling for Integrating Several Endpoints in Alzheimer’s Disease Drug Trials

Thursday 15:00-16:30

IV-075Thanakorn Vongjarudech

Evaluation of QT Prolongation During Bedaquiline Treatment Using a Time-Varying Tuberculosis-Specific Correction Factor (QTcTBT)

Thursday 15:00-16:30

IV-076Paul Vrenken

Development of a novel open-source Physiology-Based Biopharmaceutics Modelling (PBBM) framework using the Open System Pharmacology suite

Thursday 15:00-16:30

IV-077My Luong Vuong

Multiple imputation to handle missing covariate data in pharmacometrics modelling

Thursday 15:00-16:30

IV-078Axel Vuorinen

A comparative analysis of Bayesian dose-finding designs incorporating pharmacokinetics information

Thursday 15:00-16:30

IV-079Zhigang Wang

Time-to-event modelling and simulation of the risk of relapse after infusion interval extension of infliximab in patients with inflammatory bowel diseases

Thursday 15:00-16:30

IV-080Shayne Watson

Population PK and PKPD modeling of TBA-7371 in Healthy Adults and Adults with tuberculosis

Thursday 15:00-16:30

IV-081Sebastian Weber

Novel integrated population PD modeling framework to inform decision making during Oncology phase I dose-escalation

Thursday 15:00-16:30

IV-082Franz Weber

Successful validation of a model-informed precision dosing instrument for meropenem in critically ill patients, the DoseCalculator, against NONMEM®

Thursday 15:00-16:30

IV-083Haini Wen

Translational physiologically based pharmacokinetic modeling to predict human pulmonary kinetics after inhalation

Thursday 15:00-16:30

IV-084Dominic Whittaker

Leveraging in vitro data from novel drug candidates to prioritize antibody combinations in autoimmune disease using a QSP model of IBD

Thursday 15:00-16:30

IV-085Ella Widigson

Model-derived PK target profile of ustekinumab therapeutic thresholds in inflammatory bowel diseases to guide precision dosing

Thursday 15:00-16:30

IV-086Marie Wijk

A pragmatic approach to handling data below the lower limit of quantification in complex pharmacokinetic models

Thursday 15:00-16:30

IV-087Mélanie Wilbaux

How to handle population pharmacokinetics modeling in the context of a regulatory submission for a compound already well-characterized in other settings? A case-study with nivolumab in urothelial cancer.

Thursday 15:00-16:30

IV-088Francis Williams Ojara

Population pharmacokinetic characterisation of plasma-to-breast milk transfer of lamivudine and subsequent infant exposure through breast milk

Thursday 15:00-16:30

IV-089Insa Winzenborg

Uncovering Bias in Exposure-Response Relationships: Investigating the Impact of Exposure Calculation for Irregular Dosing Regimens

Thursday 15:00-16:30

IV-090Daniel Wojtyniak

Influential factors on the type I error rate in pharmacometrics models using individual model averaging or standard approach

Thursday 15:00-16:30

IV-091Jan-Georg Wojtyniak

Population Pharmacokinetics of Survodutide in Subjects with Overweight or Obesity with and without Type 2 Diabetes Mellitus Based on Phase I and Phase II Data

Thursday 15:00-16:30

IV-092Yin Cheong Wong

Population pharmacokinetic/pharmacodynamic modeling to evaluate target suppression in patients with advanced solid tumors by ginisortamab, an anti-gremlin-1 monoclonal antibody

Thursday 15:00-16:30

IV-093Jen-Hao (Eric) Wu

Clinical trial design evaluation in pediatric oncology: Phase I dose finding trial design optimization exemplified by brigatinib (ITCC-098)

Thursday 15:00-16:30

IV-095Maria Xiberras

External Validation of a Population Pharmacokinetic Model for Morphine and its Metabolites in Children under 3 Years who Underwent Cardiothoracic Surgery

Thursday 15:00-16:30

IV-097Liang Yang

A combined model meta-analysis of aggregated and individual FEV1 data from randomized COPD trials

Thursday 15:00-16:30

IV-098Eunsol Yang

Translational tool-based phase 2 clinical outcome predictions of the novel diarylquinoline TBAJ-587 for the treatment of tuberculosis, compared to bedaquiline and TBAJ-876

Thursday 15:00-16:30

IV-099Koichiro Yoneyama

Impact of Imbalanced Baseline Responses among Dose Levels in the Exposure-Response Analysis by Nonlinear Mixed-Effect Modeling

Thursday 15:00-16:30

IV-100Huifang You

Machine learning time-to-event analysis for prediction of 2-month culture conversion with phase 2a information in tuberculosis drug development

Thursday 15:00-16:30

IV-101Simone Zannoni

The impact of weekend dosing holidays on the evaluation of the sterilizing efficacy of different 4-drug combinations in a relapsing mouse model of Mycobacterium tuberculosis infection using a logistic Emax model

Thursday 15:00-16:30

IV-102Javier Zarzoso Foj

Individualized dosing regimen optimization of ustekinumab through a population pharmacokinetic-pharmacodynamic model in patients with psoriasis

Thursday 15:00-16:30

IV-103Tatiana Zasedateleva

Local TMDD of large molecules in tissue interstitial space

Thursday 15:00-16:30

IV-104Hinojal Zazo Gómez

Dosing evaluation of ceftazidime/avibactam in intensive care unit patients based on pharmacokinetic-pharmacodinamic (PK/PD) modelling and simulation.

Thursday 15:00-16:30

IV-105Stefan Zeiser

A population PK analysis of docetaxel after IV administration of CPC634 (CriPec® docetaxel) and generic docetaxel in plasma and tumor

Thursday 15:00-16:30

IV-106Mengxu Zhang

Exploring the contribution of brain metabolism in mechanistic understanding of Kp,uu,BBB – A case study for remoxipride

Thursday 15:00-16:30

IV-107Tan Zhang

The impact of drug properties and severity of obesity on renal clearance through glomerular filtration and active tubular secretion

Thursday 15:00-16:30

IV-108Renwei Zhang

Impact of censoring on non-linear effect modeling of aggregate-level survival data

Thursday 15:00-16:30

IV-109Xiao Zhang

Assessment of Sample Size Allocation for A Multi-regional Phase 2 Trial: Comparison of Statistical and Dose-Exposure-Response (D-E-R) Approaches

Thursday 15:00-16:30

IV-110Xiaonan Zhang

Assessing the Effect of Pneumonia on Tigecycline Lung Exposure Using Physiological-Based Pharmacokinetic Modelling

Thursday 15:00-16:30

IV-111Qiaolin Zhao

Population pharmacokinetic analysis for pediatric patients with inflammatory bowel disease receiving infliximab

Thursday 15:00-16:30

IV-112Kirill Zhudenkov

A model-based survival meta-analysis for indirect comparison of immune therapy efficacy in NSCLC

Thursday 15:00-16:30

IV-113Manuela Zimmermann

NLME modelling from a causal inference perspective when the dose-exposure-response relationship is confounded by the treatment regimen

Thursday 15:00-16:30

IV-114Jochen Zisowsky

Target-mediated drug disposition of monoclonal antibody binding to plasma soluble target: some insights from PBPK/PD and popPK/PD approaches

Thursday 15:00-16:30

IV-115Yuanxi Zou

Pharmacokinetics and dosing of dispersible moxifloxacin formulation in children with rifampicin-resistance tuberculosis

Thursday 15:00-16:30

IV-116Laura Zwep

Statistical interaction modeling in non-linear mixed effect models: a case study in neonatal pharmacology

Thursday 15:00-16:30